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Abstract
Background: It is not known why survival differs between men and women in oxygen-dependent chronic obstructive
pulmonary disease (COPD). The present study evaluates differences in comorbidity between men and women, and tests the
hypothesis that comorbidity contributes to sex-related differences in mortality in oxygen-dependent COPD.
Methods: National prospective study of patients aged 50 years or older, starting long-term oxygen therapy (LTOT) for COPD
in Sweden between 1992 and 2008. Comorbidities were obtained from the Swedish Hospital Discharge Register. Sex-related
differences in comorbidity were estimated using logistic regression, adjusting for age, smoking status and year of inclusion.
The effect of comorbidity on overall mortality and the interaction between comorbidity and sex were evaluated using Cox
regression, adjusting for age, sex, PaO2 breathing air, FEV1, smoking history and year of inclusion.
Results: In total, 8,712 patients (55% women) were included and 6,729 patients died during the study period. No patient
was lost to follow-up. Compared with women, men had significantly more arrhythmia, cancer, ischemic heart disease and
renal failure, and less hypertension, mental disorders, osteoporosis and rheumatoid arthritis (P,0.05 for all odds ratios).
Comorbidity was an independent predictor of mortality, and the effect was similar for the sexes. Women had lower
mortality, which remained unchanged even after adjusting for comorbidity; hazard ratio 0.73 (95% confidence interval,
0.68–0.77; P,0.001).
Conclusions: Comorbidity is different in men and women, but does not explain the sex-related difference in mortality in
oxygen-dependent COPD.
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Introduction
Severe Chronic Obstructive Pulmonary Disease (COPD) can be
a devastating illness with high morbidity and mortality. [1] Long-
term oxygen therapy (LTOT) is an established treatment in
hypoxic (oxygen-dependent) COPD, as it was shown to approx-
imately double survival in two randomized trials. [2,3] The
incidence of LTOT has increased markedly in women; in fact, the
majority of patients starting LTOT in Sweden are now women.
[4] Studies of sex-related differences in survival on LTOT for
COPD have shown conflicting results. Women had better survival
than men after starting LTOT in most studies, [4,5,6,7] but in a
study of Machado et al., survival was worse in women than men.
[8] These inconsistent findings could be related to the heteroge-
neity of research settings, patient selection and covariates included
in the analyses. Co-existing diseases, or comorbidity, was only
evaluated in two of the studies, which both found a high overall
prevalence of comorbidity but did not report any significant
differences in comorbidity between men and women. [7,8]
Interestingly, one study found that comorbidity predicted
mortality, but only in women. [7] It remains unknown whether
the effect of comorbidity on mortality differs between men and
women, as this has only been evaluated in one previous, relatively
small, study, which found no effect measure interaction between
comorbidity and sex. [8]
The prevalence of comorbidity in COPD is high, [9] and
increases with age and COPD severity. [10,11] Comorbidity has
been shown to predict mortality in COPD, [11,12] and may be
more prevalent in men than in women. [11,13] An analysis from
the TORCH study, in which patients with significant comorbidity
were excluded, found no significant difference in mortality
between men and women. [14] In a study of patients matched
in terms of COPD severity, [13] mortality was found to be higher
in men than in women, and comorbidity to predict mortality in
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35806men only. This study formulated the hypothesis that the higher
mortality in men was attributable to sex-dependent differences in
comorbidity, especially in severe COPD. [14]
The present national prospective study evaluates whether there
are differences in comorbidity between men and women in
oxygen-dependent COPD, and tests the hypothesis that comor-
bidity contributes to sex-related differences in mortality.
Materials and Methods
Patients aged 50 years or older, starting LTOT for physician
diagnosed COPD between 1 January 1992 and 31 December
2008 in the Swedish National Oxygen Register were included
prospectively. The indications for LTOT and details of the register
have been reported previously, [4] and part of the database was
used in recently published studies. [15,16] For patients who had
started LTOT more than once (n=99), only the latest treatment
episode was included in the analysis. At baseline, defined as the
date of starting LTOT, data were collected on arterial gas tension
of oxygen (PaO2) and carbon dioxide (PaCO2) when breathing air
and during oxygen therapy, forced expiratory volume in one
second (FEV1), forced vital capacity (FVC), concomitant home
mechanical ventilator use, smoking history (never, past or current
smoking), the prescribed oxygen dose, and the prescribed duration
of oxygen therapy per day.
Discharge diagnoses, the number of hospitalizations and in-
hospital days within five years prior to starting LTOT were
collected for all patients from the Swedish Hospital Discharge
Register, which covers more than 98% of all hospitalizations in
Sweden after 1 January 1987. [17] In addition, data on all lung
transplantations and lung volume reduction procedures before
starting LTOT and during follow up was collected.
Patients were followed until withdrawal of LTOT, death or 31
December 2008, whichever came first. Vital status and underlying
cause of death was obtained from the Swedish Causes of Death
Register. All diagnoses, procedure codes, and causes of death were
coded according to the ninth (before 1997) and tenth revisions of
the International Classification of Disease (ICD). [18,19] Defini-
tions of all diagnosis entities and procedures are found in a
supporting information table (Table S1).
Ethics statement
All patients gave their informed written consent to participate.
The study was approved by the Lund University Research Ethics
Committee (157/2007 and 350/2008), the Swedish National
Board of Health and Welfare, and the Data Inspection Board.
Statistical methods
Differences in baseline data were tested using chi square-test,
Student’s t-test, and Wilcoxon’s rank-sum test for categorical,
normally and non-normally distributed variables. Comorbidities
were defined as relevant registered discharge diagnoses, primary
or secondary, within five years prior to starting LTOT. In the
analyses, comorbidity was categorized into the Charlson comor-
bidity score, [20] with COPD removed from the list of weighted
diagnoses, in order to only include comorbidities of COPD. Age
was not incorporated in the Charlson score and was included as an
independent variable in all analyses.
Odds ratios for women as compared to men for individual
comorbidities and for the Charlson score, adjusted for age,
smoking history and start year, were analyzed using logistic
regression and a generalized ordered logit model. [21] The
ordered odds ratio for Charlson score was interpreted as the odds
ratio of having a higher score than the present category. [21] The
Hosmer-Lemeshow test was used to test the fit of the logistic
models. [22]
The effect of comorbidity, categorized as Charlson score and
individual diagnoses not included in the score, on overall mortality
was evaluated using Cox regression, [23] adjusted for age, sex,
PaO2 breathing air, FEV1 (included as absolute values or percent
of predicted, [24] respectively), start year and smoking history.
The effect of adding body mass index (BMI) to the model was
evaluated in the cohort starting LTOT 1995–2008, as BMI was
registered during this time period only. Interactions between
comorbidity and sex, age and start year, respectively, and between
age and sex were analyzed on the multiplicative scale by entering
interaction terms into the fully adjusted model. Biological
interaction between sex and comorbidity (defined as a Charlson
score of one or higher) on the additive scale was explored by
calculating the adjusted attributable proportion, which is the
proportion of the relative risk among exposed that is attributable
to the interaction, [25] adjusted for all covariates in the Cox
regression. The attributable risk among all men was calculated as:
[the attributable proportion]6[the prevalence of Charlson score
one or more among men].
The proportional hazards assumption of the Cox model was
assessed graphically with log-log plots and by testing for
interaction with analysis time for all covariates. The overall fit of
the model was assured using Cox-Snell residuals.
All statistical tests were two-sided and P-values below the
standard value of 0.05 were considered statistically significant. All
confidence intervals were 95% intervals. All statistical analyses
were performed with Stata version 11.1 (StataCorp LP; College
Station, TX).
Results
A total of 8,712 patients, 3,929 men and 4,783 (54.9%) women
were included in the study after exclusion of 15 patients (0.2%)
because of data irregularities. Concomitant home mechanical
ventilator was used at baseline by 2% of both women and men.
Lung transplantation was performed in only 7 patients before
starting LTOT, and in 45 (0.5%) patients, 29 women and 16 men,
during follow up. Only 60 patients (27 women) had had lung
volume reduction surgery before starting LTOT, and during
follow up, it was performed in 17 patients (8 women). The cohort
was followed for a total of 20718.7 person-years with a median
follow-up of 1.65 years (range 0–16.85 years). LTOT was
withdrawn before death in 415 patients (4.8%), mainly owing to
improved oxygenation. No patient was lost to follow up. In total,
6,729 patients, 3,199 men and 3,530 women, died under
observation. Nonrespiratory causes of deaths were slightly more
common in men than women (31.1% vs 27.4%; P=0.001).
Baseline characteristics are shown in Table 1. Compared with
men, women were younger, had a lower mean absolute FEV1 but
similar FEV1% of predicted, higher PaCO2, and more in-hospital
days, although the median number of hospitalizations were the
same as for men. In the subset of patients starting LTOT 1995 or
later (n=7593), the mean BMI [6 SD] was 23.065.1 and
23.566.7 kg/m
2 in men and women, respectively.
Of all patients, 98.3% had been hospitalized at least once within
five years prior to starting LTOT and 75% three or more times.
The patients who had no hospitalization (1.7%) were evenly
distributed between men (N=77) and women (n=73).
Sex-related differences in comorbidity
As shown in Table 2, women had more hypertension, mental
disorders, osteoporosis and rheumatoid arthritis, but less arrhyth-
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to men. There were no significant sex-related differences for
anemia, cerebrovascular disease, diabetes mellitus, digestive organ
disease, heart failure, lung cancer or pulmonary embolism. Men
were more likely to have high Charlson scores than women, and
this sex-related difference increased with each additional category
in the Charlson score (Table 3).
Comorbidity and mortality
Comorbidity was an independent predictor of adjusted
mortality, with increasing mortality for each additional category
in the Charlson score (Table 4). In addition, anemia, arrhythmia,
mental disorders and osteoporosis, which are not included in the
Charlson score, independently predicted mortality. When indi-
vidual diagnoses were entered in the model instead of the Charlson
score, the comorbidities which were statistically significant and
increased mortality with 10% or more were anemia, arrhythmia,
cancer, ischemic heart disease, heart failure, mental disorder, and
osteoporosis (Table 5).
The crude overall mortality was lower for women than for men,
hazard ratio (HR) 0.76 (95% confidence interval (CI), 0.73–0.80;
P,0.001). As shown in Table 4 and 5, this survival benefit for
women was not explained by comorbidity, since it remained
relatively unchanged in multiple regression models which adjusted
for Charlson score and individual comorbidities, as well as the
other covariates. The sex-related difference remained unchanged
even after adjusting, in addition to the covariates above, for the
number of hospitalizations in the preceding five years or when
excluding patients with no prior hospitalization, HR 0.73 (95%
CI, 0.68–0.77; P,0.001) and HR 0,73 (95% CI, 0.68–0.78;
P,0.001), respectively. In addition, the model estimates remained
unchanged when including BMI and FEV1 in percent of predicted
instead of the absolute values, as shown in the supplemental Table
S2. There were no signs of multiplicative interaction between
comorbidity and sex; P-values for interaction terms ranging 0.669–
0.842, or comorbidity and age (P ranging 0.108–0.924),
comorbidity and start year (P ranging 0.100–0.862), or age and
sex (P ranging, 0.436–0.892). Although not statistically significant,
data indicated a small biological interaction between comorbidity
and sex on the additive scale, attributable proportion 0.073 (95%
CI; 20.01, 0.16). Thus, interaction may have attributed to 7.3%
of the relative risk in men with comorbidity, and 3.7% of the
relative risk among all men.
Discussion
The main findings in the present study are that in oxygen-
dependent COPD 1) comorbidity differs between men and
women, 2) comorbidity is an independent predictor of mortality
with similar effects for both sexes, and 3) comorbidity does not
explain the survival difference between men and women.
To the authors’ knowledge, this is the first study to evaluate sex-
related differences in the prevalence of individual diagnosis entities
in a large cohort of patients with oxygen-dependent COPD. The
only two previous studies of sex-stratified comorbidity in the field
included relatively few patients and found no significant difference
in the mean number of comorbidities [7] or Charlson score, [8]
respectively.
The higher prevalence of cardiovascular disease among men is
consistent with previous studies of patients with a broader range of
COPD-severity. [11,26] The finding of more hypertension among
women than men is consistent with some previous studies, [26,27]
but not all. [11] The lack of sex-related difference in heart failure
in the present study, in spite of a previous report of a higher
prevalence among men, [11] might be due to the differences in
patient selection and the particular difficulty of detecting heart
failure in severe COPD. For this reason, the heart failure estimates
should be interpreted with caution. Interestingly, mental disorders
Table 1. Baseline characteristics of patients starting long-term oxygen therapy for chronic obstrucitve pulmonary disease, 1992–
2008.
Characteristic Women, n=4,783 (55%) Men, n=3,929 P-value
Age, years 71.868.4 73.767.8 ,0.001
PaO2 air, kPa 6.560.9 6.760.9 ,0.001
PaCO2 air, kPa 6.561.2 6.161.2 ,0.001
PaO2 oxygen, kPa 8.861.1 8.961.1 ,0.001
PaCO2 oxygen, kPa 6.861.2 6.361.2 ,0.001
FEV1,L 0 . 7 60.3 1.060.5 ,0.001
FEV1 of predicted, % 34.0617.0 35.5619.6 0.005
FVC, L 1.560.5 2.260.9 ,0.001
Smoking history, %
Never 6 4 ,0.001
Past 91 94 ,0.001
Current 3 2 0.129
All Hospitalizations, n
* 5 (3–9) 5 (3–9) 0.013
Hospitalizations for COPD, n
* 2 (1–4) 2 (1–4) ,0.001
In-hospital days
* 48 (25–87) 41 (21–77) ,0.001
Data presented as mean 6 SD unless otherwise specified.
Definition of abbreviations: FEV1=forced expiratory volume in one second; FVC=forced vital capacity; PaCO2 air=arterial blood gas tension of carbon dioxide while
breathing ambient air; PaCO2 oxygen=arterial blood gas tension of carbon dioxide while breathing oxygen; PaO2 air=arterial blood gas tension of oxygen while
breathing ambient air; PaO2 oxygen=arterial blood gas tension of oxygen while breathing oxygen.
*Hospitalizations and in-hospital days within 5 years prior to starting LTOT, presented as median (first quartile – third quartile).
doi:10.1371/journal.pone.0035806.t001
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findings that female sex is a determinant of depression in COPD.
[28]
In the present study, comorbidity predicted mortality, indepen-
dent of age, sex, degree of hypoxia, FEV1, year of starting LTOT,
and smoking status. Previous studies of whether Charlson score
predicts mortality in COPD have shown conflicting results,
[7,8,10,11,12,13,29,30,31] which may be due to relatively small
study populations, [7,29] inclusion of few women, [12,29,30] or
inclusion of covariates that captured part of the effect of
comorbidity in the multiple regression models, such as dyspnea,
measures of physical capacity and quality of life, [8,13] which may
have biased the estimates for comorbidity toward less effect.
Although often used, the Charlson score has not been validated in
COPD. In the present study, several comorbidities predicted
mortality independent of the Charlson score, which was also found
in another recent study. [31] This highlights the need for an
updated comorbidity score validated specifically for COPD.
A previous study of our group showed that women had a better
adjusted survival than men in oxygen-dependent COPD, but that
this unexplained survival advantage for women also exists in the
Swedish general population. [16] In fact, women had higher
relative mortality than men, when the mortality was compared
with the expected mortality in the general population for women
and men respectively. [16] The driving hypothesis behind the
present study was that differences in comorbidity, which was not
evaluated in the previous study, explain part of the survival
advantage for women compared with men after starting LTOT for
COPD. [4,5,6,7] Surprisingly, the present findings strongly argue
against any such effect on the sex-related difference in survival.
Furthermore, the effect of comorbidity on the mortality rate-ratio
was not modified by sex, and any biological interaction was small.
Thus, the longer survival for women as compared with men is not
Table 2. Prevalence and sex-related odds of comorbidity in patients starting long-term oxygen therapy for chronic obstructive
pulmonary disease, 1992–2008.
Diagnosis
Prevalence in Women,
n( % )
Prevalence in Men,
n( % )
Adjusted Odds Ratio for
Women Compared to Men
*
95% Confidence
Interval P-value
All cancers
{ 460 (10) 503 (13) 0.74 0.64–0.84 ,0.001
Lung cancer 76 (2) 79 (2) 0.74 0.53–1.02 0.065
Anaemia 245 (5) 183 (5) 1.11 0.90–1.36 0.329
Arrhythmia
{ 578 (12) 662 (17) 0.72 0.63–0.81 ,0.001
Cerebrovascular disease 236 (5) 214 (5) 0.88 0.73–1.08 0.224
Diabetes mellitus 414 (9) 369 (9) 0.87 0.74–1.01 0.062
Digestive organ disease 922 (19) 831 (21) 0.90 0.81–1.01 0.062
Heart failure 1543 (32) 1254 (32) 1.09 0.99–1.20 0.072
Hypertension
{ 673 (14) 429 (11) 1.26 1.10–1.1.45 0.001
Ischemic heart disease
{ 864 (18) 880 (22) 0.77 0.69–0.86 ,0.001
Mental disorder
{ 482 (10) 291 (7) 1.27 1.09–1.49 0.003
Osteoporosis
{ 485 (10) 131 (3) 3.42 2.80–4.19 ,0.001
Pulmonary embolism 114 (2) 89 (2) 0.99 0.74–1.32 0.931
Renal failure
{ 72 (2) 101 (3) 0.58 0.42–0.79 0.001
Rheumatoid arthritis
{ 103 (2) 52 (1) 1.56 1.10–2.20 0.012
Percentages may not add up to 100 due to rounding.
*Odds ratio adjusted for age, smoking history and year of starting long-term oxygen therapy.
{Entities with significant sex-related difference in odds.
doi:10.1371/journal.pone.0035806.t002
Table 3. Prevalence and sex-related odds of Charlson score in patients starting long-term oxygen therapy for chronic obstructive
pulmonary disease, 1992–2008.
Charlson
score Prevalence in Women, n (%) Prevalence in Men, n (%)
Adjusted Odds Ratio for
Women Compared to Men
*
95% Confidence
Interval P-value
0 2440 (51) 1962 (50) 1.00 0.91–1.09 0.921
1 1371 (29) 1012 (26) 0.79 0.71–0.88 ,0.001
2 616 (13) 517 (13) 0.62 0.53–0.72 ,0.001
3 224 (5) 235 (6) 0.49 0.39–0.62 ,0.001
.3 132 (3) 203 (5) - - -
Percentages may not add up to 100 due to rounding.
*Generalized ordered odds ratio adjusted for age, smoking history and year of inclusion. It is interpreted as the odds ratio of having a higher score than the present
category.
doi:10.1371/journal.pone.0035806.t003
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of comorbidity on mortality.
The strength of the present study is the prospective inclusion of
a large national cohort of patients starting LTOT for COPD with
complete follow-up. The National Oxygen Register covers some
85% of all patients who have started LTOT since 1987 in Sweden,
with loss of data from whole counties mainly due to temporary
shortages of staff. [32]
Several potential weaknesses in the present study need to be
mentioned. This study included patients starting LTOT and the
distribution of comorbidities and their effects on mortality may not be
representative for the whole population of patients with very severe
COPD. Although diagnoses in the Swedish Hospital Discharge
Register have been recently validated as having high specificity
throughout as well as good sensitivity to certain conditions, such as
cardiovascular disease, the register’s sensitivity is lower for less acute
or less serious conditions, such as hypertension and diabetes mellitus.
[33] The sensitivity for cardiovascular diseasemight be lower inthese
patients with severe COPD than indicated by the validation studies,
as cardiac disease may remain undiagnosed. [34] The misclassifica-
tion from low sensitivity would likely tend to underestimate the
association between these comorbidities and mortality, as unregis-
tered comorbidity in the ‘‘healthy’’ group will make their mortality
more similar to that of patients with registered comorbidity. [35] On
the other hand, the estimates for comorbidities may be biased
towards a higher effect, as patients with more severe illness may be
more likely to be hospitalized and to get comorbidities registered.
However, a too high effect of comorbidity is not a threat to the
validity of the present finding that comorbidity does not explain the
sex-related difference in mortality. We lacked data on prognostic
predictors such as the level of dyspnea and exercise capacity, but
inclusion of these factors, which are likely directly related to
comorbidity, would have biased the associations between comorbid-
ity and mortality. There were also insufficient data on duration and
severity of comorbidities, but the sensitivity of the Discharge Register
has been shown to be high for serious and more severe forms of
comorbidity, [33] known to have prognostic impact in COPD. Thus,
the present finding that comorbidity cannot explain sex-related
differences in mortality is likelyto have a high validity. In the authors’
opinion, thementioned potentialweaknessesdo not substantially alter
the main finding of the present study.
What could be the mechanisms behind the survival difference
between men and women in oxygen-dependent COPD, [4,5,6,7]
since it does not seem to be explained by comorbidity? The present
data do not suggest that women started LTOT earlier in the course
of their disease, or had less severe respiratory insufficiency, since
FEV1% of predicted were similar and women in fact had a lower
mean PaO2 and a higher mean PaCO2 on ambient air than men
when starting LTOT. Whether the effect of LTOT or the
compliance to the therapy differs between the sexes has not been
evaluated because few women were included in the randomized
trials and compliance has generally not been assessed. [2,3] One
hypothesis is that women, as compared to men, might develop
COPD at lower smoking exposure [36] and report more dyspnea
and lower quality of life independent of COPD severity. [27,37] It is
possible that women, due to less total smoking and different
exposure to other biological factors (such as sexhormones) as well as
environmental factors (such as alcohol, social and nutritional
factors), might have lower frailty with the same degree of respiratory
insufficiency than men after starting LTOT. There may also be
phenotypical differences between men and women in COPD. Men
have been found to have more emphysema than women at all levels
of COPD severity and smoking, [38] which could contribute to the
survivaldifferencesincetheextentofemphysemapredictsmortality.
Table 4. Cox regression of overall mortality in patients
starting long-term oxygen therapy, 1992–2008.
Characteristic Hazard ratio
95% confidence
interval P-value
Age 1.04 1.04–1.04 ,0.001
Female 0.73 0.68–0.77 ,0.001
PaO2 air 0.88 0.86–0.91 ,0.001
FEV1 0.82 0.76–0.88 ,0.001
Past smoking
* 1.05 0.94–1.20 0.356
Current smoking
* 1.33 1.07–1.64 0.010
Start year 1.00 1.00–1.01 0.391
Charlson score
{
1 1.14 1.07–1.22 ,0.001
2 1.39 1.26–1.52 ,0.001
3 1.52 1.32–1.75 ,0.001
.3 1.69 1.42–2.02 ,0.001
Anemia 1.28 1.10–1.48 0.001
Arrhythmia 1.23 1.13–1.34 ,0.001
Mental disorder 1.18 1.06–1.32 0.003
Osteoporosis 1.31 1.17–1.48 ,0.001
Definition of abbreviations: FEV1=forced expiratory volume in one second; PaO2
air=arterial blood gas tension of oxygen while breathing ambient air.
*Never smoking is used as reference category.
{Charlson score 0 is used as reference category.
doi:10.1371/journal.pone.0035806.t004
Table 5. Cox regression of the effects of individual
comorbidities on overall mortality.
Characteristic
Hazard
ratio
95% confidence
interval P-value
Age 1.04 1.04–1.04 ,0.001
Female 0.72 0.68–0.77 ,0.001
PaO2 air 0.88 0.85–0.91 ,0.001
FEV1 0.81 0.75–0.87 ,0.001
Past smoking
* 1.08 0.95–1.23 0.228
Current smoking
* 1.36 1.10–1.69 0.005
Start year 1.00 1.00–1.01 0.300
All cancers 1.28 1.17–1.41 ,0.001
Anemia 1.31 1.12–1.52 ,0.001
Arrhythmia 1.24 1.14–1.36 ,0.001
Cerebrovascular disease 1.01 0.88–1.16 0.914
Diabetes mellitus 1.11 1.00–1.24 0.060
Heart failure 1.10 1.03–1.17 0.006
Hypertension 1.03 0.93–1.14 0.591
Ischemic heart disease 1.12 1.04–1.21 0.004
Mental disorder 1.17 1.05–1.31 0.005
Osteoporosis 1.30 1.15–1.47 ,0.001
Pulmonary embolism 1.20 0.96–1.50 0.101
Renal failure 1.11 0.87–1.43 0.394
Rheumatoid arthritis 1.15 0.93–1.42 0.197
*Never smoking is used as reference category.
doi:10.1371/journal.pone.0035806.t005
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LTOT warrants further research.
For the clinician, this study shows that comorbidity has a major
impact on mortality even in the most severe stages of COPD and
highlights the importance of improved preventive treatments for
conditions such as osteoporosis, as well as of optimized diagnosis
and treatment of manifest comorbidity in order to improve the
high morbidity and mortality in severe COPD.
In conclusion, this study shows that comorbidity differs between
men and women, but differences in prevalence or effect of
comorbidity do not explain the sex-related difference in mortality
in oxygen-dependent COPD.
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